DBVT
USDDBV Technologies S.A. American Depositary Shares
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$14.050
高値
$15.010
安値
$14.050
出来高
0.07M
企業ファンダメンタルズ
時価総額
521.2M
業種
バイオテクノロジー
国
France
取引統計
平均出来高
0.10M
取引所
NCM
通貨
USD
52週レンジ
関連ニュース
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a clinical-stage
HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $20
HC Wainwright & Co. analyst Andrew S. Fein maintains DBV Technologies with a Buy and raises the price target from $16 to $20.
